Research programme: targeted EZH2 inhibitors - Epizyme/Eisai

Drug Profile

Research programme: targeted EZH2 inhibitors - Epizyme/Eisai

Alternative Names: EPZ 5687; EPZ005687; EZH2 inhibitors - Epizyme/Eisai

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme
  • Class Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Lymphoma; Solid tumours

Most Recent Events

  • 13 Mar 2018 Epizyme has patents issued and pending for targeted EZH2 inhibitors in countries worldwide
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Lymphoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top